Investing News NetworkOctober 08, 2024Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ('Cardiol' or the 'Company'), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce the Company has filed a preliminary prospectus supplement (the 'Supplement') to its short form base shelf prospectus dated July 12, 2024 (the 'Base Prospectus') in connection with a proposed public offering (the 'Offering') of Class A common shares (the 'Common Shares').

投资新闻网2024年10月8日Cardiol Therapeutics Inc.（NASDAQ:CRDL）（TSX:CRDL）（“Cardiol”或“公司”）是一家临床阶段生命科学公司，专注于抗炎和抗纤维化治疗心脏病的研究和临床开发，很高兴地宣布，该公司已于2024年7月12日就拟议的a类普通股（以下简称“普通股”）公开募股（以下简称“发行”）提交了一份初步招股说明书补充（以下简称“补充说明书”）。

The Supplement was also filed with the U.S. Securities Exchange and Commission (the 'SEC'), as part of a registration statement on Form-10, as amended, which was declared effective by the SEC on July 16, 2024, in accordance with the Multijurisdictional Disclosure System established between Canada and the United States.The Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis, and for general and administrative expenses, working capital and other expenses.

根据加拿大和美国之间建立的多司法管辖区信息披露制度，该补充文件还作为经修订的表格10登记声明的一部分提交给了美国证券交易委员会（“SEC”），该登记声明于2024年7月16日由SEC宣布生效。该公司打算使用此次发行的净收益来支持CardiolRx的临床开发，用于治疗复发性心包炎，以及一般和管理费用、营运资金和其他费用。

Canaccord Genuity is acting as the sole bookrunner in connection with the Offering.The Offering is expected to be priced in the context of the market, with the final terms of the Offering to be determined at the time of pricing. There can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering.

Canaccord Genuity是此次发行的唯一簿记管理人。预计此次发行将在市场背景下定价，发行的最终条款将在定价时确定。无法保证发售是否或何时完成，也无法保证发售的实际规模或条款。

The closing of the Offering will be subject to customary closing conditions, including the listing of the Common Shares on the Toronto Stock Exchange (the 'TSX') and the Nasdaq Capital Market (the 'Nasdaq') and any required approvals of the TSX and Nasdaq.The Supplement and accompanying Base Pr.

本次发行的结束将取决于惯例的结束条件，包括普通股在多伦多证券交易所（“TSX”）和纳斯达克资本市场（“Nasdaq”）上市，以及TSX和Nasdaq所需的任何批准。补充和附带的基础Pr。